CABERGOLINE Tablets — Class III drug recall D-128-2013
Terminated recall by Teva Pharmaceuticals USA, Inc., reported 2013-01-23, distributed nationwide. Impurities/Degradation Products: This lot of product will not meet the impurity specification over shelf life
| Recall number | D-128-2013 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Inc., Sellersville, PA, United States |
| Recall initiated | 2012-04-24 |
| Classified | 2013-01-16 |
| Reported by FDA | 2013-01-23 |
| Terminated | 2013-12-18 |
| Distributed | Nationwide (US) |
| Quantity | 13,232 bottles |
| Reason classes | specification failure |
| NDC | 00093-5420, 00093-5420-88 |
| Lot numbers | 07/12, 6A007046V |
Product
CABERGOLINE Tablets, 0.5 mg, RX only, 8 count bottles, Manufactured For: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960 NDC 0093-5420-88
Reason for recall
Impurities/Degradation Products: This lot of product will not meet the impurity specification over shelf life
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-128-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.